ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey Sells 19,341 Shares

Key Points

• Director Thomas Haughey sold 19,341 shares of ANI Pharmaceuticals at an average price of $85.93, resulting in a 34.62% decrease in his holdings.
• ANI Pharmaceuticals reported $1.80 earnings per share for the last quarter, surpassing analysts' estimates and achieving a 53.2% year-over-year revenue growth.
• Hedge funds have shown significant interest in ANI Pharmaceuticals, with 76.05% of the stock now owned by institutional investors, some increasing their stakes by as much as 89.3%.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) Director Thomas Haughey sold 19,341 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total value of $1,661,972.13. Following the sale, the director directly owned 36,521 shares of the company's stock, valued at $3,138,249.53. This represents a 34.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $1.26 on Thursday, reaching $90.00. 604,501 shares of the company's stock were exchanged, compared to its average volume of 623,678. The company has a fifty day moving average of $67.34 and a 200-day moving average of $64.62. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $90.23. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -116.88 and a beta of 0.61. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business's revenue for the quarter was up 53.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.02 earnings per share. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ANIP. Millennium Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Aberdeen Group plc lifted its position in shares of ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock worth $28,059,000 after buying an additional 181,134 shares during the last quarter. Woodline Partners LP acquired a new stake in ANI Pharmaceuticals in the first quarter valued at about $11,144,000. Deep Track Capital LP grew its position in ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after acquiring an additional 144,214 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in ANI Pharmaceuticals by 3,156.3% in the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company's stock valued at $9,617,000 after acquiring an additional 142,854 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ANIP. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday. Piper Sandler restated an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Finally, Guggenheim reissued a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.